A Blog from the Lymphoma Program at Weill Cornell Medicine and NewYork-Presbyterian
Dr. Ari Melnick Discusses EZH2 as a Potential Target in Diffuse Large B Cell Lymphoma
Last week Weill Cornell researcher Dr. Ari Melnick sat down with Targeted Oncology to briefly summarize the potential of EZH2 in treating diffuse large B-cell lymphoma.
Located on the Upper East Side of New York City, the Lymphoma Program at Weill Cornell Medical College/NewYork Presbyterian Hospital is internationally recognized for our efforts to enable patients with non-Hodgkin lymphoma, Hodgkin disease and related disorders to have the best possible clinical outcome, including cure when possible.
View all posts by lymphomaprogram
New Developments in Lymphoma 